This review covers some of the recent advances in understanding PCa, including identification and targeting of key genetic aberrations (ERG,SPOP, and DNA repair defects), improvements in disease models, the emergence of AR-negative disease, and current immunotherapy strategies. This evidence concerns the gene AR and posterior cortical atrophy.